RU2015129640A - Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1 - Google Patents
Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1 Download PDFInfo
- Publication number
- RU2015129640A RU2015129640A RU2015129640A RU2015129640A RU2015129640A RU 2015129640 A RU2015129640 A RU 2015129640A RU 2015129640 A RU2015129640 A RU 2015129640A RU 2015129640 A RU2015129640 A RU 2015129640A RU 2015129640 A RU2015129640 A RU 2015129640A
- Authority
- RU
- Russia
- Prior art keywords
- antigen
- disulfide
- terminus
- multifunctional protein
- antibody
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title claims 17
- 108090000623 proteins and genes Proteins 0.000 title claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 27
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 17
- 229920001184 polypeptide Polymers 0.000 claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims 16
- 235000018102 proteins Nutrition 0.000 claims 16
- 239000000427 antigen Substances 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 11
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 6
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 6
- 230000004927 fusion Effects 0.000 claims 6
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims 5
- 108010075704 HLA-A Antigens Proteins 0.000 claims 5
- 108010058607 HLA-B Antigens Proteins 0.000 claims 4
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 4
- 230000005867 T cell response Effects 0.000 claims 4
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 claims 3
- 108010052199 HLA-C Antigens Proteins 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12198904 | 2012-12-21 | ||
| EP12198904.0 | 2012-12-21 | ||
| EP13175469 | 2013-07-08 | ||
| EP13175469.9 | 2013-07-08 | ||
| PCT/EP2013/077109 WO2014096015A1 (en) | 2012-12-21 | 2013-12-18 | Disulfide-linked multivalent mhc class i comprising multi-function proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015129640A true RU2015129640A (ru) | 2017-01-26 |
Family
ID=49779923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015129640A RU2015129640A (ru) | 2012-12-21 | 2013-12-18 | Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10501521B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2935328B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6475167B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20150097688A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104884474A (cg-RX-API-DMAC7.html) |
| AR (1) | AR094149A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013360775B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2889788A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2700984T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1214276A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL238499B (cg-RX-API-DMAC7.html) |
| MX (1) | MX361076B (cg-RX-API-DMAC7.html) |
| PL (1) | PL2935328T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2015129640A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201504414UA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014096015A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| WO2014083004A1 (en) * | 2012-11-30 | 2014-06-05 | Roche Glycart Ag | Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins |
| RU2015129640A (ru) | 2012-12-21 | 2017-01-26 | Ф.Хоффманн-Ля Рош Аг | Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1 |
| CN105899229A (zh) | 2013-11-04 | 2016-08-24 | Uti有限合伙公司 | 用于持续的免疫治疗的方法和组合物 |
| ES2727552T3 (es) * | 2015-02-18 | 2019-10-17 | Hoffmann La Roche | Inmunoconjugados para la inducción específica de la citotoxicidad de los linfocitos T frente a una célula diana |
| WO2016198932A2 (en) | 2015-05-06 | 2016-12-15 | Uti Limited Partnership | Nanoparticle compositions for sustained therapy |
| BR112018073606A2 (pt) | 2016-05-18 | 2019-02-26 | Cue Biopharma, Inc. | polipeptídeos multiméricos moduladores de células t e métodos de uso dos mesmos |
| DK3538559T3 (da) | 2016-11-09 | 2025-07-14 | Uti Lp | Rekombinante pmhc klasse ii-molekyler |
| WO2018119114A1 (en) * | 2016-12-22 | 2018-06-28 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| EP3596118B1 (en) | 2017-03-15 | 2024-08-21 | Cue Biopharma, Inc. | Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer |
| CN111741746A (zh) | 2017-11-29 | 2020-10-02 | 乌第有限合伙公司 | 治疗自身免疫性疾病的方法 |
| EP3737689A4 (en) | 2018-01-09 | 2021-12-01 | Cue Biopharma, Inc. | MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF |
| CA3100576A1 (en) * | 2018-06-20 | 2019-12-26 | Danmarks Tekniske Universitet | Scaffolds with stabilized mhc molecules for immune-cell manipulation |
| WO2020056152A1 (en) * | 2018-09-12 | 2020-03-19 | Chang Liu | Single chain constructs |
| DE102018122546B3 (de) * | 2018-09-14 | 2019-12-05 | Immatics Biotechnologies Gmbh | Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden |
| CN113412123A (zh) * | 2018-12-28 | 2021-09-17 | 豪夫迈·罗氏有限公司 | 用于免疫应答增强的患者的治疗性用途的肽-mhc-i-抗体融合蛋白 |
| US11346844B2 (en) | 2019-04-26 | 2022-05-31 | Protein Metrics Inc. | Intact mass reconstruction from peptide level data and facilitated comparison with experimental intact observation |
| AU2020282736B2 (en) * | 2019-05-29 | 2025-10-30 | Cue Biopharma, Inc. | Multimeric T-cell modulatory polypeptides and methods of use thereof |
| EP4087653A4 (en) * | 2020-01-10 | 2024-06-19 | Dyne Therapeutics, Inc. | MUSCLE TARGETING COMPLEXES AND RELATED USES FOR THE TREATMENT OF MYOTONIC DYSTROPHY |
| EP4106790A4 (en) * | 2020-02-21 | 2024-02-21 | 3T Biosciences, Inc. | YEAST DISPLAY LIBRARIES, RELATED COMPOSITIONS AND RELATED METHODS OF USE |
| AU2021272895A1 (en) | 2020-05-12 | 2022-09-22 | Cue Biopharma, Inc. | Multimeric T-cell modulatory polypeptides and methods of use thereof |
| AU2021309842A1 (en) * | 2020-07-14 | 2023-02-16 | Cue Biopharma, Inc. | T-cell modulatory polypeptides with conjugation sites and methods of use thereof |
| EP4211149A4 (en) | 2020-09-09 | 2024-10-09 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF |
| CA3210307A1 (en) * | 2021-02-07 | 2022-08-11 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Bispecific antibody |
| WO2023023641A2 (en) * | 2021-08-20 | 2023-02-23 | 3T Biosciences, Inc. | Peptide-hla-b*35 libraries, associated compositions, and associated methods of use |
| CN115838432B (zh) * | 2022-07-08 | 2023-12-08 | 浙江大学 | 一种靶向调控抗原特异性t细胞的融合蛋白及应用 |
| WO2025113640A1 (zh) * | 2023-11-30 | 2025-06-05 | 南京维立志博生物科技股份有限公司 | 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2095818B (en) | 1981-03-27 | 1985-10-02 | Exxon Research Engineering Co | Staged adsorption/resorption heat pump |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5238808A (en) | 1984-10-31 | 1993-08-24 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| DE3825615A1 (de) | 1988-07-28 | 1990-02-01 | Behringwerke Ag | Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung |
| ZA898290B (en) | 1988-11-03 | 1991-06-26 | Igen Inc | Electrochemiluminescent assays |
| US5068088A (en) | 1988-11-03 | 1991-11-26 | Igen, Inc. | Method and apparatus for conducting electrochemiluminescent measurements |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| JPH03240498A (ja) | 1990-02-16 | 1991-10-25 | Nobuyoshi Shimizu | 抗体およびそれを使用した免疫分析方法 |
| IL100866A (en) | 1991-02-06 | 1995-10-31 | Igen Inc | Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6268411B1 (en) | 1997-09-11 | 2001-07-31 | The Johns Hopkins University | Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| PT994903E (pt) | 1997-06-24 | 2005-10-31 | Genentech Inc | Metodos e composicoes para glicoproteinas galactosiladas |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6361964B1 (en) * | 1997-08-12 | 2002-03-26 | Massachusetts Institute Of Technology | Eukaryotic disulfide bond-forming proteins and related molecules and methods |
| EP1028751B1 (en) | 1997-10-31 | 2008-12-31 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| EP1068241B1 (en) | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Antibody variants and fragments thereof |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| US7521197B2 (en) | 1998-06-05 | 2009-04-21 | Alexis Biotech Limited | Method for producing cytotoxic T-cells |
| WO1999064597A1 (en) | 1998-06-10 | 1999-12-16 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | β2 MICROGLOBULIN FUSION PROTEINS AND HIGH AFFINITY VARIANTS |
| PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING A POLYPEPTIDE |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| AU5532601A (en) | 2000-04-12 | 2001-10-30 | Univ Rochester | Targeted vaccine delivery systems |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| EP3263702A1 (en) | 2000-10-06 | 2018-01-03 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| GB0103998D0 (en) | 2001-02-19 | 2001-04-04 | King S College London | Method |
| US20030017134A1 (en) * | 2001-06-19 | 2003-01-23 | Technion Research And Development Foundation Ltd. | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
| RU2321630C2 (ru) | 2001-08-03 | 2008-04-10 | Гликарт Биотекнолоджи АГ | Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
| US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| WO2003084570A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM |
| US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
| US7749753B2 (en) | 2002-04-09 | 2010-07-06 | Kyowa Hakko Kirin Co., Ltd | Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost |
| PL373256A1 (en) | 2002-04-09 | 2005-08-22 | Kyowa Hakko Kogyo Co, Ltd. | Cells with modified genome |
| US20030199024A1 (en) | 2002-04-19 | 2003-10-23 | Hansen Ted H. | Single chain trimers of class I MHC molecules |
| US8895020B2 (en) | 2002-04-19 | 2014-11-25 | Washington University | Single chain trimers and uses therefor |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2004056312A2 (en) | 2002-12-16 | 2004-07-08 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| ES2383014T3 (es) | 2003-04-02 | 2012-06-15 | F. Hoffmann-La Roche Ag | Anticuerpos contra el factor I de crecimiento similar a insulina y usos de los mismos |
| US20050042218A1 (en) * | 2003-07-10 | 2005-02-24 | Vaccinex, Inc. | MHC class I - peptide-antibody conjugates with modified beta2-microglobulin |
| CA2542046A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
| WO2005035778A1 (ja) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法 |
| RS55723B1 (sr) | 2003-11-05 | 2017-07-31 | Roche Glycart Ag | Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| JP4633788B2 (ja) | 2004-04-13 | 2011-02-16 | エフ．ホフマン−ラ ロシュ アーゲー | 抗ｐ−セレクチン抗体 |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2007025554A1 (en) | 2005-08-29 | 2007-03-08 | Medizinische Hochschule Hannover | Method for the generation of antigen-specific t-cells and uses thereof |
| US20080014203A1 (en) | 2006-04-11 | 2008-01-17 | Silke Hansen | Antibodies against insulin-like growth factor I receptor and uses thereof |
| US7977457B2 (en) | 2006-05-19 | 2011-07-12 | Teva Pharmaceutical Industries Ltd. | Fusion proteins, uses thereof and processes for producing same |
| US20080138354A1 (en) * | 2006-07-21 | 2008-06-12 | City Of Hope | Cytomegalovirus vaccine |
| US8992937B2 (en) | 2006-08-28 | 2015-03-31 | Washington University | Disulfide trap MHC class I molecules and uses therefor |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| WO2009039854A2 (en) * | 2007-09-27 | 2009-04-02 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
| RU2379055C1 (ru) | 2008-04-30 | 2010-01-20 | Виктор Владимирович Кешелава | Способ лечения онкологических заболеваний |
| HUE040326T2 (hu) | 2011-02-10 | 2019-03-28 | Roche Glycart Ag | Mutáns interleukon-2 polipeptidek |
| MX354663B (es) * | 2011-06-22 | 2018-03-14 | Hoffmann La Roche | Eliminación de células diana por parte de células t citotóxicas específicas de virus utilizando complejos que comprenden mhc de clase i. |
| RU2015129640A (ru) | 2012-12-21 | 2017-01-26 | Ф.Хоффманн-Ля Рош Аг | Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1 |
| WO2016198932A2 (en) | 2015-05-06 | 2016-12-15 | Uti Limited Partnership | Nanoparticle compositions for sustained therapy |
-
2013
- 2013-12-18 RU RU2015129640A patent/RU2015129640A/ru not_active Application Discontinuation
- 2013-12-18 JP JP2015548483A patent/JP6475167B2/ja not_active Expired - Fee Related
- 2013-12-18 WO PCT/EP2013/077109 patent/WO2014096015A1/en not_active Ceased
- 2013-12-18 AU AU2013360775A patent/AU2013360775B2/en not_active Ceased
- 2013-12-18 HK HK16102155.9A patent/HK1214276A1/zh unknown
- 2013-12-18 US US14/745,170 patent/US10501521B2/en not_active Expired - Fee Related
- 2013-12-18 MX MX2015007239A patent/MX361076B/es active IP Right Grant
- 2013-12-18 KR KR1020157019208A patent/KR20150097688A/ko not_active Ceased
- 2013-12-18 CA CA2889788A patent/CA2889788A1/en not_active Abandoned
- 2013-12-18 SG SG11201504414UA patent/SG11201504414UA/en unknown
- 2013-12-18 ES ES13808036T patent/ES2700984T3/es active Active
- 2013-12-18 CN CN201380066835.0A patent/CN104884474A/zh active Pending
- 2013-12-18 EP EP13808036.1A patent/EP2935328B1/en not_active Not-in-force
- 2013-12-18 PL PL13808036T patent/PL2935328T3/pl unknown
- 2013-12-19 AR ARP130104873A patent/AR094149A1/es unknown
-
2015
- 2015-04-28 IL IL238499A patent/IL238499B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP2935328A1 (en) | 2015-10-28 |
| EP2935328B1 (en) | 2018-10-10 |
| US20150344586A1 (en) | 2015-12-03 |
| KR20150097688A (ko) | 2015-08-26 |
| IL238499A0 (en) | 2015-06-30 |
| CA2889788A1 (en) | 2014-06-26 |
| PL2935328T3 (pl) | 2019-02-28 |
| AR094149A1 (es) | 2015-07-15 |
| US10501521B2 (en) | 2019-12-10 |
| MX361076B (es) | 2018-11-27 |
| JP6475167B2 (ja) | 2019-02-27 |
| CN104884474A (zh) | 2015-09-02 |
| JP2016501900A (ja) | 2016-01-21 |
| MX2015007239A (es) | 2015-08-12 |
| AU2013360775B2 (en) | 2018-04-12 |
| SG11201504414UA (en) | 2015-07-30 |
| AU2013360775A1 (en) | 2015-05-14 |
| WO2014096015A1 (en) | 2014-06-26 |
| ES2700984T3 (es) | 2019-02-20 |
| HK1214276A1 (zh) | 2016-07-22 |
| IL238499B (en) | 2018-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015129640A (ru) | Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1 | |
| RU2015125639A (ru) | Удаление раковых клеток с помощью циркулирующих вирус-специфических цитотоксических т-клеток с использованием направленных против раковых клеток многофункциональных белков, содержащих молекулу гкгс класса i | |
| JP7138046B2 (ja) | 二特異性抗体基幹 | |
| JP2014519830A5 (cg-RX-API-DMAC7.html) | ||
| JP2020511949A5 (cg-RX-API-DMAC7.html) | ||
| JP2019521643A5 (cg-RX-API-DMAC7.html) | ||
| RU2015152077A (ru) | Тримерные антигенсвязывающие молекулы | |
| JP2018519803A5 (cg-RX-API-DMAC7.html) | ||
| EA201400046A1 (ru) | Удаление клеток-мишеней с помощью циркулирующих вирусспецифических цитотоксических т-клеток с использованием содержащих гкгс класса i комплексов | |
| FI3665192T3 (fi) | Muunneltuja transferriinireseptoria sitovia polypeptidejä | |
| JP2020511113A5 (cg-RX-API-DMAC7.html) | ||
| JP2017509335A5 (cg-RX-API-DMAC7.html) | ||
| JP2020517294A5 (cg-RX-API-DMAC7.html) | ||
| AR077088A1 (es) | Proteinas biespecificas de union a antigeno | |
| RU2018138703A (ru) | Слитые полипептиды cd40l-fc и способы их применения | |
| JP2019522466A5 (cg-RX-API-DMAC7.html) | ||
| KR20160014010A (ko) | 신규 항체 | |
| JP2015527869A5 (cg-RX-API-DMAC7.html) | ||
| JP2012025766A5 (cg-RX-API-DMAC7.html) | ||
| JP2012025737A5 (cg-RX-API-DMAC7.html) | ||
| CN121159719A (zh) | 具有可调的亲和力的免疫调节蛋白 | |
| EA200870555A1 (ru) | Слитые белки, их применение и способы их получения | |
| JP2016533174A5 (cg-RX-API-DMAC7.html) | ||
| JP2017512063A5 (cg-RX-API-DMAC7.html) | ||
| EP2970508A2 (en) | Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180613 |